Positive early stage data bode well for DICE Therapeutics’ (Nasdaq: DICE) goal of developing a novel oral therapeutic for the treatment of psoriasis.
DICE shares jumped more than 60% on Monday, after the firm announced positive top-line data from its Phase I trial of DC-806, an oral IL-17 blocker.
The Californian immunology company said the results demonstrated proof-of-concept for the candidate, with a 43.7% reduction of symptoms in the high dose group, compared to 13.3% in the placebo group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze